Lindsey Rolfe - Nov 1, 2022 Form 4 Insider Report for Clovis Oncology, Inc. (CLVS)

Role
Officer
Signature
/s/ Lindsey Rolfe
Stock symbol
CLVS
Transactions as of
Nov 1, 2022
Transactions value $
-$4,188
Form type
4
Date filed
11/3/2022, 04:15 PM
Previous filing
Sep 6, 2022
Next filing
Jun 15, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CLVS Common Stock Options Exercise +3.75K +3.42% 113K Nov 1, 2022 Direct F1
transaction CLVS Common Stock Sale -$1.88K -1.91K -1.68% $0.98* 111K Nov 2, 2022 Direct F2, F3
transaction CLVS Common Stock Options Exercise +4.63K +4.15% 116K Nov 1, 2022 Direct F1
transaction CLVS Common Stock Sale -$2.31K -2.35K -2.03% $0.98* 114K Nov 2, 2022 Direct F2, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction CLVS Restricted Stock Units Options Exercise $0 -3.75K -49.99% $0.00 3.75K Nov 1, 2022 Common Stock 3.75K Direct F1, F4
transaction CLVS Restricted Stock Units Options Exercise $0 -4.63K -16.67% $0.00 23.1K Nov 1, 2022 Common Stock 4.63K Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit represents the right to receive one share of Common Stock.
F2 Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the Restricted Stock Units listed in Table II. This sale does not represent a discretionary trade by the reporting person.
F3 This transaction was executed in multiple trades at prices ranging from $ 0.9621 to $9.9830. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4 On February 1, 2019, the reporting person was granted 59,988 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2020, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.
F5 On January 31, 2020, the reporting person was granted 74,000 Restricted Stock Units. 25% of such Restricted Stock Units vested on February 1, 2021, and the remainder vests in substantially equal installments over the 12 quarters immediately following such date.

Remarks:

Chief Medical Officer and Executive Vice President of Clinical and Preclinical Development and Pharmacovigilance